
    
      This is a two-phase study consisting of 8 weeks of open label treatment with sertraline
      (50-200 mg/day) in patients with SAD and in those who fail to demonstrate symptom remission
      on sertraline alone, 8 weeks of randomized, double-blind, placebo-controlled augmentation
      with ziprasidone.
    
  